Prognostic Utility of Pre- and Postoperative KRAS-Mutated ctDNA in Resected Pancreatic Ductal Adenocarcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Prognostic utility of preoperative and postoperative KRAS-mutated circulating tumor DNA (ctDNA) in resected pancreatic ductal adenocarcinoma: A systematic review and meta-analysis
Surg Oncol 2023 Dec 01;51(xx)102007, A Alqahtani, A Alloghbi, P Coffin, C Yin, R Mukherji, BA WeinbergFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.